Home LiteratureArticle Details
PMID: 16614850 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide.

Cancer chemotherapy and pharmacology ·Vol. 59 ·No. 1 ·2007-01-00 ·Pages 127-36

Moreb JS, Mohuczy D, Muhoczy D, Ostmark B, Zucali JR

Abstract

Aldehyde dehydrogenases class-1A1 (ALDH1A1) and class-3A1 (ALDH3A1) have been associated with resistance to cyclophosphamide (CP) and its derivatives. We have previously reported the downregulation of these enzymes by all-trans retinoic acid (ATRA). In this study, we used siRNA duplexes as well as retrovirally expressed siRNA to knockdown one or both enzymes together in A549 lung cancer cell line in order to investigate the role of each one in mediating the resistance and the effect of the addition of ATRA. The results show that significant and specific knockdown of each enzyme can be achieved and that each one contributes similarly to cell resistance to 4-hydroperoxycyclophosphamide (4-HC), an active derivative of CP. Added effects were seen when both enzymes were inhibited. The addition of ATRA also exhibited additional inhibitory effects on ALDH activity and increased 4-HC toxicity when added to single siRNA aimed at one of the enzymes. On the other hand, ATRA had minimal and insignificant additional inhibitory effects on ALDH enzyme activity when added to a combination of siRNAs against both enzymes, but still increased 4-HC toxicity beyond that seen with RNAi-mediated inhibition of both enzymes together. We conclude that both enzymes, ALDH1A1 and ALDH3A1 will need to be blocked in order to achieve the highest sensitivity to 4-HC. Furthermore, ATRA increases 4-HC toxicity even when added to a combination of siRNAs against both enzymes, thus suggesting additional mechanisms by which ATRA can increase drug toxicity.

MeSH Terms
Actins/biosynthesis Aldehyde Dehydrogenase/genetics Aldehyde Dehydrogenase 1 Family Antineoplastic Agents/pharmacology Blotting, Western Cell Line, Tumor Cyclophosphamide/analogs & derivatives,pharmacology DNA Primers Drug Resistance, Neoplasm/genetics Humans Lung Neoplasms/enzymology,genetics RNA Interference/physiology Retinal Dehydrogenase Retroviridae/genetics Substrate Specificity Tretinoin/metabolism,pharmacology
Chemicals
Actins Antineoplastic Agents DNA Primers Tretinoin Cyclophosphamide Aldehyde Dehydrogenase 1 Family ALDH3A1 protein, human Aldehyde Dehydrogenase ALDH1A1 protein, human Retinal Dehydrogenase perfosfamide
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Moreb Jan S
Department of Medicine, Division of Hematology/Oncology, University of Florida, College of Medicine, 1600 SW Archer Road, Room R4-220, PO Box 100277, Gainesville, FL 32610, USA. morebjs@medicine.ufl.edu
Mohuczy Dagmara
Muhoczy Dagmara
Ostmark Blanca
Zucali James R
Article Info
Journal
Cancer chemotherapy and pharmacology
Abbr.
Cancer Chemother Pharmacol
ISSN
0344-5704
Published
2007-01-00
Epub
2006-00-14
Pages
127-36
Language
English
Region
Germany
NLM ID
7806519
Subset
IM
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com